COVID-19 Delays Planned Trial of PTC743 and Gene Therapy Work, PTC Says
The COVID-19 pandemic will delay development work on a potential gene therapy, and the start of a planned and possibly pivotal clinical trial in the small molecule treatment PTC743, both intended for people with Frederich’s ataxia (FA), PTC Therapeutics said in a quarterly report. PTC now expects to start…
